Industries
Biotechnology & Biologics
Biologics manufacturing carries process variability, comparability obligations and contamination control demands that a generic quality system does not accommodate well. We help biotechnology organizations build controls that reflect the actual process.
xFDA supports biologics and biotechnology organizations with manufacturing quality systems, contamination control, process and cleaning validation, comparability documentation, laboratory controls and supplier quality — matched to consultants with verified biologics manufacturing experience.
How we support this sector
Where engagements typically focus
- Cell banking, upstream and downstream process controls
- Comparability strategy across process changes and scale-up
- Viral safety, bioburden and contamination control programs
- Single-use system qualification and supplier controls
- Aseptic fill-finish compliance and sterility assurance
- Bioassay and analytical method lifecycle in QC laboratories
We work with clinical-stage and commercial biologics organizations, including companies transferring processes to or from contract manufacturers.
When companies call us
Situations we are asked into
- A process is transferring from a development group to a CDMO and the receiving site has different equipment.
- Environmental monitoring excursions are recurring in a fill-finish suite.
- Comparability after a process change needs to be documented defensibly.
- Single-use system suppliers have never been formally qualified.
- A clinical-stage quality system needs to mature before commercial manufacturing.
Questions we are asked
Biotechnology & Biologics: common questions
Direct answers from the consultants who do this work.
- How is a biologics quality system different from a small-molecule one?
- The regulations are largely shared, but the risk profile is not. Biologics carry process-derived variability, living-system contamination risk and comparability obligations across changes, so the control strategy has to be built around process understanding and contamination control rather than end-product testing.
- What is contamination control strategy documentation expected to contain?
- A holistic description of how facility design, personnel flow, material flow, utilities, environmental monitoring, sterilization/sanitization and process controls work together to control bioburden and viable/non-viable contamination, along with the data used to justify each control.
- When does a process change require a comparability exercise?
- When the change can plausibly affect product quality attributes — cell bank, media, scale, purification steps, formulation or primary container. The exercise should be pre-defined with acceptance criteria based on the product's quality attributes, not assembled after results are in hand.
- Do you support aseptic and sterile fill-finish operations?
- Yes, where consultant experience supports it. Work commonly includes aseptic process simulation design and review, intervention analysis, gowning qualification, environmental monitoring program redesign and sterility assurance investigations.
- Can you support a virtual biotech that relies entirely on a CDMO?
- Yes. Sponsor oversight is the core issue: person-in-plant expectations, quality agreements, batch record review, deviation notification obligations and technical review of the CDMO's validation and investigation output.
Technical guidance for this sector
- Process ValidationProcess validation for a drug product is a three-stage lifecycle: design the process and its control strategy, qualify commercial-scale performance, and then verify that the process stays in control for as long as it is used.
- Cleaning ValidationCleaning validation demonstrates that a documented cleaning procedure consistently reduces residues to scientifically justified limits on shared equipment.
- cGMP ConsultingcGMP consulting for a drug manufacturer means making 21 CFR Parts 210 and 211 operable in your facility — with procedures your staff can follow, records that reconstruct what happened and a quality unit with the authority to act.
- Technology TransferTechnology transfer succeeds or fails on what the receiving site is given: process understanding, not just a batch record.
- Quality SystemsA pharmaceutical quality system is the set of connected processes — documents, changes, deviations, CAPA, training, release, review — that keep product decisions defensible.
- Data IntegrityLaboratory data integrity is a question of whether every reported result can be reconstructed from complete, attributable, contemporaneous records.
- Method ValidationMethod validation demonstrates that an analytical procedure is suitable for its intended purpose.
- IND SupportFor an IND, the section that most often holds up a program is CMC.
- BLA SupportFor a biologic, the process is a substantial part of the product.
- IND CMC SupportSponsors filing an IND usually need two things at once: CMC content for the application and a quality system capable of overseeing clinical manufacturing.
Newsletter
Insights from Former FDA & Industry Experts
Practical perspectives on GMP, quality systems, validation, manufacturing and development — written by the consultants doing the work. No newsletter-only sales pitches.
Start a project
Tell us what you're working on.
Describe the product, the process or the problem. We will tell you honestly whether we are the right people to help, and who should be on the team if we are.